AstraZeneca
FDA Approves Lynparza as Adjuvant Therapy With Myriad Genetics CDx for BRCA-Mutated Breast Cancer
Updated data from the pivotal OlympiA trial that led the drug's approval shows AstraZeneca and Merck's PARP inhibitor improves survival compared to placebo.
Genomenon, Alexion Pharmaceuticals Team on Rare Disease Dx
Genomenon will apply its AI-driven technology to develop a "genomic landscape" for specific conditions and combine those data with therapy and trial information.
Thermo Fisher Scientific, AstraZeneca Team up to Develop CDx for Targeted Drugs
The next-generation sequencing based companion diagnostics will be paired with targeted therapies that are being developed for several diseases.
Genecast to Evaluate Liquid Biopsy EGFR Mutation Test in Early-Stage Non-Small Cell Lung Cancer
The firm hopes its qPCR-based liquid biopsy test could help identify early-stage NSCLC patients eligible for adjuvant or neoadjuvant anti-EGFR TKI treatment.
In Brief This Week: Unilabs, PerkinElmer, Invitae, Becton Dickinson, and More
News items for the in vitro diagnostics industry for the week of April 19, 2021.
Feb 25, 2021
Mar 29, 2019